Table 5.
Comparison between C3435T and G2677T genotypes regarding tacrolimus side effects
| Variables | N (%) | |||
|---|---|---|---|---|
| C3435T | CC (N = 26) | CT (N = 35) | TT (N = 22) | P value |
| Nephrotoxicity | 5 (19.2%) | 10 (28.6%) | 5 (22.7%) | 0.690 |
| Neurotoxicity | 1 (3.8%) | 1 (2.9%) | 5 (22.7%) | 0.670 |
| NODAT | 0 (0%) | 1 (2.9%) | 0 (0%) | 0.500 |
| Dyslipidemia | 1 (3.8%) | 2 (5.7%) | 1 (4.5%) | 0.943 |
| hirsutism | 0 (0%) | 1 (2.9%) | 0 (0%) | 0.500 |
| G2677T | GG (N = 19) | GT (N = 44) | TT (N = 20) | P value |
| Nephrotoxicity | 9 (39.1%) | 8 (21.6%) | 3 (13.0%) | 0.105 |
| Neurotoxicity | 0 (0%) | 1 (2.7%) | 1 (4.3%) | 0.622 |
| NODAT | 1 (4.3%) | 0 (0%) | 0 (0%) | 0.554 |
| Dyslipidemia | 1 (4.3%) | 2 (5.4%) | 1 (4.3%) | 0.975 |
| hirsutism | 1 (4.3%) | 0 (0%) | 0 (0%) | 0.554 |
TAC; tacrolimus, N; number, C; cytosine, T; thymine, G; guanine, NODAT; new onset diabetes after transplantation, Chi square test was used for comparison